

Letter of the Chairman of the Supervisory Board

Dear Shareholders,

on behalf of the Supervisory Board of Fresenius Medical Care AG & Co. KGaA, I would like to thank you for your investment into our Company in these very turbulent times.

Once again in the past year, we performed the tasks entrusted to us as a supervisory body and representative of shareholders' interests in an intensive and constructive dialog with the Management Board. Based on these discussions, I would again like to give you a summary in the run-up to our virtual Annual General Meeting on May 12, 2022, on the developments which have impacted Fresenius Medical Care's business in the past year. These trends are also likely to remain with us in the coming months.

Unfortunately, and in contrast to our initial expectations, Fresenius Medical Care's entire year 2021 was marked by the COVID-19 pandemic – without any doubt the biggest global challenge of the past decades. From today's point of view, we believe that the effects of the pandemic will impact us in the year 2022 as well.

Employees of Fresenius Medical Care across all business segments have shown an unparalleled commitment to ensure the life-sustaining dialysis treatments for our more than 300,000 patients worldwide and partially under pandemic-related difficult circumstances. We are conscious and very appreciative of the fact that our employees have often gone above and beyond the call of duty in the past two years. On behalf of the entire Supervisory Board, I want to thank all employees and the Management Board from the bottom of my heart for their tireless commitment.

To protect our patients and employees in the COVID-19 pandemic and to maintain safe operations at our more than 4,000 dialysis centers and 44 production sites worldwide we, for example, continued to provide personal protective equipment. As frequently reported in the media, clinical staff is becoming more and more scarce. The situation is extraordinarily tight in the U.S. healthcare services market, which is so important to our business. We aim to safeguard the life-sustaining dialysis treatments for our patients with the aid of temporary labor and personnel retention measures. These and numerous other measures increase our costs in the Dialysis Services business. In contrast to the year 2020, where these strongly elevated costs were partially compensated by government support particularly in the U.S., substantially lower funding was provided in the year 2021 for this purpose. In addition, the capacity utilization in our dialysis clinics, in the other parts of our

value chain, as well as in our product business was considerably reduced due to the pandemic. These developments led to the substantial decline in Group results.

What lies in store for us in the year 2022? On one hand, we will continue to be confronted by the effects of the pandemic. This is reflected in a continued lower capacity utilization in our dialysis clinics following the COVID-19-related excess mortality in our patient population and the resulting adverse effects on the other areas of our value chain. Safeguarding adequate staffing of our clinics will be a huge challenge and incur additional costs. On the other hand, we anticipate underlying patient growth and initial cost savings from our transformation program FME25. Consequently, we are aiming to return to earnings growth.

At this time, we cannot assess what the long-term consequences of the current geopolitical unrests in Ukraine will be. While Russia and Ukraine make up less than one percent of our Group revenues and our life-sustaining products continue to be exempt from sanctions, the substantially increased energy and raw material prices will additionally burden our business development – particularly if these remain elevated longer term.

The Supervisory Board will use its entire expertise and collective years of experience to support the Management Board in this difficult environment. In its role as advisor to the Management Board, the Supervisory Board has always been and continues to be very closely involved in fundamental decisions. The transformation program FME25 and the business strategy are ongoing topics of discussion: this is about improving the positioning of Fresenius Medical Care and strengthening the Company in the long term as well as the targeted increase in shareholder value.

Pursuant to new legal provisions, there is a new agenda item in this year's Annual General Meeting. Management Boards and Supervisory Boards of listed companies must prepare a compensation report every year. The compensation report for fiscal year 2021 presents in detail the compensation components awarded or due in fiscal year 2021 to the current and former members of the Management Board and the Supervisory Board of the General Partner as well as the current and former members of the Supervisory Board of the Company. This agenda item does not constitute a vote on the compensation system or the level of compensation. The respective compensation systems were already resolved in the Annual General Meeting 2020 with a 95.05% approval rate for the Management Board remuneration and a 98.52% approval rate for the Supervisory Board remuneration.

The compensation report was reviewed by the auditor to determine whether the legally required disclosures were made. In addition to the statutory requirements, the content of

the report was also reviewed by the auditor. This prepared and audited compensation report must be submitted to the Annual General Meeting for approval.

The compensation report for fiscal year 2021 including the auditor's note is included in the convening notice to the Annual General Meeting following the agenda under Section II. The report is part of the convening notice to the Annual General Meeting and is also available on the Company's website. Our recommendation is to approve the compensation report for the fiscal year 2021.

It goes without saying that your participation in the business success of Fresenius Medical Care is also an important factor in our considerations. As you know, our dividend policy both aims to pay out dividends based on the business performance in the respective fiscal year and strives to ensure dividend continuity. The mid- and long-term perspectives of our Company remain very positive. Fresenius Medical Care will again consistently grow after overcoming the pandemic and, in particular, with the execution of the transformation program FME25, which is why we focus on dividend continuity this year. We will propose to the Annual General Meeting the distribution of a dividend of €1.35 per share. This would be the 25th consecutive increase in dividend, even if the increase this year has more of a symbolic nature.

Fresenius Medical Care will successfully master the challenges resulting from the pandemic and the geopolitical instabilities. In particular, the execution of the transformation program FME25 will result in two business segments with clear responsibilities, with which Fresenius Medical Care will be more efficiently organized and better positioned to exploit the future growth potential along the renal care continuum and beyond, as the Company has defined in its Strategy 2025. The establishment of sustainable partnerships with payors worldwide will enable Fresenius Medical Care to deliver medical added value and, at the same time, make care affordable in value-based care models. Fresenius Medical Care's longstanding experience in value-based care and the largest database in the industry relating to patients with chronic kidney disease, will help slow down the progression of kidney disease and reduce hospitalizations with the aid of proprietary forecasting models. To improve the quality of life for patients and offer them a broader range of therapy, Fresenius Medical Care will further expand its home dialysis services. Accordingly, the Company has set itself new targets to this end.

If you have any questions in the run-up to the Annual General Meeting that cannot be answered at the event itself, please do not hesitate to contact our Investor Relations team.

The year 2022 will hopefully lead us out of the pandemic and find positive solutions for the strained geopolitical landscape. We are setting the course for long-term and profitable

growth for our Company. At the same time, we will act socially responsible and conduct our business in a sustainable and environmentally friendly manner. I would like to thank you for your confidence in the Supervisory Board.

Yours sincerely,

A handwritten signature in black ink, appearing to read 'DSchenk', written in a cursive style.

Dr. Dieter Schenk

Bad Homburg, March 2022

Chairman of the Supervisory Board

Fresenius Medical Care AG & Co. KGaA